Analysis of Physicochemical and Structural Properties Determining HIV-1 Coreceptor Usage

PLoS Computational Biology

Volumn 9, Issue 3, 2013, Pages

  Bozek, Katarzyna ^a   Lengauer, Thomas ^a   Sierra, Saleta ^b   Kaiser, Rolf ^b   Domingues, Francisco S ^c  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c University of Lubeck   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; FORECASTING; PATIENT TREATMENT; STRUCTURAL PROPERTIES;

BLOCKINGS; CORECEPTORS; DESCRIPTORS; DISEASE PROGRESSION; ENCODINGS; IDENTIFICATION OF PROPERTIES; PERCENTAGE POINTS; PREDICTION-BASED; PREDICTIVE POWER; STRUCTURE-BASED;

VIRUSES;

MARAVIROC; VIRUS PROTEIN V; VIRUS RECEPTOR;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MATHEMATICAL COMPUTING; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; RECEIVER OPERATING CHARACTERISTIC; RECEPTOR BINDING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION STUDY; VIRAL TROPISM;

EID: 84875967816     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002977     Document Type: Article

References (48)

1. Chan DC, Kim PS, (1998) HIV entry and its inhibition. Cell 93: 681-684.
2. Pierson TC, Doms RW, (2003) HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 281: 1-27.
3. Sattentau QJ, Moore JP, (1991) Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174: 407-415.
4. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, et al. (1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384: 184-187.
5. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, et al. (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183-3187.
6. Shioda T, Levy JA, Cheng-Mayer C, (1992) Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89: 9434-9438.
7. Jensen MA, van 't Wout AB, (2003) Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 5: 104-112.
8. Berger EA, Murphy PM, Farber JM, (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
9. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243.
10. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
11. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
12. Pillai S, Good B, Richman D, Corbeil J, (2003) A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19: 145-149.
13. Resch W, Hoffman N, Swanstrom R, (2001) Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62.
14. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106.
15. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, et al. (2007) Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51: 566-575.
16. German AIDS Society (2008) Empfehlung zur Bestimmung des HIV-1-Korezeptor-Gebrauchs. Available:http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/Leitlinien%20zur%20Topismus_Testung%20Stand%20Juni%202009.pdf Accessed 25 January 2013.
17. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, et al. (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis May 11: 394-407.
18. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
19. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, et al. (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317: 1930-1934.
20. Dybowski JN, Heider D, Hoffmann D, (2010) Prediction of co-receptor usage of HIV-1 from genotype. PLoS Comput Biol 6: e1000743.
21. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, et al. (2007) Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 3: e58.
22. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, et al. (1993) Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques Jul;15: 120-127.
23. Kawashima S, Ogata H, Kanehisa M, (1999) AAindex: Amino Acid Index Database. Nucleic Acids Res 27: 368-369.
24. Atchley WR, Zhao J, Fernandes AD, Druke T, (2005) Solving the protein sequence metric problem. Proc Natl Acad Sci U S A 102: 6395-6400.
25. Los Alamos HIV databases (2012) Available:http://www.hiv.lanl.gov/ Accessed 30 June 2011.
26. Breiman L, (2001) Random Forests. Mach Learn 45: 5-32.
27. Guyon I, Weston J, Barnhill S, Vapnik V, (2002) Gene Selection for Cancer Classification using Support Vector Machines. Mach Learn 46: 389-422.
28. Tibshirani R, (1996) Regression shrinkage and selection via the lasso. J Royal Statist Soc B 58: 267-288.
29. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, et al. (2004) Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids 18: F1-9.
30. Muñoz V, Serrano L, (1994) Intrinsic secondary structure propensities of the amino acids, using statistical phi-psi matrices: comparison with experimental scales. Proteins Dec 20: 301-311.
31. Crawford JL, Lipscomb WN, Schellman CG, (1973) The reverse turn as a polypeptide conformation in globular proteins. Proc Natl Acad Sci U S A Feb;70: 538-542.
32. Jones DT, Taylor WR, Thornton JM, (1992) The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci Jun;8: 275-282.
33. Isogai Y, Némethy G, Rackovsky S, Leach SJ, Scheraga HA, (1980) Characterization of multiple bends in proteins. Biopolymers Jun;19: 1183-1210.
34. Levitt M, (1978) Conformational preferences of amino acids in globular proteins. Biochemistry Oct 3;17: 4277-4285.
35. Nagano K, (1973) Logical analysis of the mechanism of protein folding. I. Predictions of helices, loops and beta-structures from primary structure. J Mol Biol Apr 5;75: 401-420.
36. Burgess AW, Ponnuswamy PK, Scheraga HA, (1974) Analysis of conformations of amino acid residues and prediction of backbone topography in proteins. Isr J Chem 12: 239-286.
37. Word JM, Lovell SC, LaBean TH, Taylor HC, Zalis ME, et al. (1999) Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. J Mol Biol 285: 1711-1733.
38. Masso M, Vaisman II, (2010) Accurate and efficient gp120 V3 loop structure based models for the determination of HIV-1 co-receptor usage. BMC Bioinformatics 11: 494.
39. Vranken WF, Budesinsky M, Fant F, Boulez K, Borremans FA, (1995) The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. FEBS Lett 374: 117-121.
40. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
41. Korber B, Foley B, Kuiken C, Pillai S, Sorodski J, (1998) Numbering positions in HIV relative to HXB2CG. Human Retrovirus and AIDS III-102-111.
42. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
43. Boser EB, Isabelle MG, Vladimir NV (1992) A training algorithm for optimal margin classifiers. In: Proceedings of the fifth annual workshop on Computational learning theory; 1992; Pittsburgh, Pennsylvania, United States: ACM. Available:http://dl.acm.org/citation.cfm?id=130401 Accessed 30 June 2011.
44. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A, (2005) e1071: Misc Functions of the Department of Statistics (e1071). TU Wien Available:http://CRAN.R-project.org/.
45. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics 21: 3940-3941.
46. Reuter S, Braken P, Jensen B, Sierra-Aragon S, Oette M, et al. Maraviroc in treatment-experienced patients with HIV-1 infection- experience from routine clinical practice. Eur J Med Res 15: 231-237.
47. Rousseeuw P, (1987) Silhouettes: A Graphical Aid to the Interpretation and Validation of Cluster Analysis. J Comput Appl Math 20: 53-65.
48. Schrodinger LLC (2010) The PyMOL Molecular Graphics System, Version 1.3r1. Available:http://www.pymol.org Accessed 30 June 2011.